Macular Degeneration Treatment Market By Type (Dry Macular Degeneration, Wet Macular Degeneration), By Treatment (Anti-VEGF Therapy, Corticosteroids, Photodynamic Therapy), and By End-User Industry (Hospitals, Ophthalmic Clinics, Ambulatory Surgery Centers); Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Macular Degeneration Treatment Market was valued at USD 4.3 Million in 2024-e and will surpass USD 9.2 Million by 2030; growing at a CAGR of 11.2% during 2025-2030.

The Macular Degeneration Treatment market focuses on managing and addressing vision loss caused by age-related macular degeneration (AMD). This progressive eye disease leads to the deterioration of the macula, impacting central vision. With increasing awareness and advancements in ophthalmic therapies, the demand for effective treatments such as Anti-VEGF therapies, corticosteroids, and photodynamic therapy has surged. Additionally, the growing geriatric population and the rising prevalence of AMD are contributing to the expansion of this market. Various end-user industries, including hospitals, ophthalmic clinics, and ambulatory surgery centers, are pivotal in providing these advanced treatments to patients.

Dry Macular Degeneration Segment is Largest Owing to its Prevalence

Dry macular degeneration (AMD) is the most common form of the condition, accounting for a significant portion of AMD cases globally. Unlike Wet AMD, which progresses rapidly, Dry AMD develops slowly and leads to gradual loss of vision over time. This subtype dominates the market due to its high prevalence among the aging population, along with limited treatment options focused on managing symptoms rather than halting progression entirely. As a result, the demand for effective monitoring and symptom management in hospitals and ophthalmic clinics remains strong, making Dry AMD a critical segment within the macular degeneration treatment market.

Anti-VEGF Therapy is Fastest Growing Due to High Efficacy

Among various treatment options, Anti-VEGF therapy has emerged as the fastest-growing segment in the macular degeneration treatment market. This therapeutic approach has demonstrated significant success in managing Wet AMD by reducing fluid leakage and slowing vision loss. The effectiveness of Anti-VEGF treatments is driving increasing adoption rates in hospitals and ophthalmic clinics, where patients seek more advanced and non-invasive solutions. Furthermore, ongoing research and development in this area continue to fuel its rapid growth, ensuring sustained market expansion.

End-User Industry Insights

Hospitals represent the largest segment in the macular degeneration treatment market, primarily due to their capability to provide comprehensive eye care services and advanced therapies under one roof. These institutions cater to a wide range of patients and have the necessary infrastructure for complex treatments like Photodynamic Therapy and Anti-VEGF injections. On the other hand, Ambulatory Surgery Centers (ASCs) are emerging as a fast-growing end-user segment, driven by their efficiency in offering outpatient procedures such as Anti-VEGF therapy, with reduced waiting times and lower costs for patients.

Largest Region: North America

North America stands as the largest region in the macular degeneration treatment market due to the high prevalence of AMD, robust healthcare infrastructure, and significant investments in ophthalmic research. The United States, in particular, has been at the forefront of advanced treatment options like Anti-VEGF and gene therapy. Additionally, favorable reimbursement policies for innovative treatments and a highly sophisticated healthcare system contribute to the dominance of this region.

Competitive Landscape

The macular degeneration treatment market is characterized by strong competition among key players such as Novartis, Regeneron Pharmaceuticals, Roche, and Bayer. These companies continuously invest in research and development, striving to introduce innovative therapies that offer improved patient outcomes. With the growing demand for advanced treatments, collaborations and partnerships are increasingly forming between pharmaceutical firms and biotech companies to explore novel solutions. As the landscape evolves, smaller players are also entering the market, driving further innovation and enhancing treatment availability.

Recent Developments:

• Novartis launched a new phase III trial for their innovative anti-VEGF therapy targeting Wet AMD in late 2024.
• Regeneron Pharmaceuticals announced FDA approval for its latest combination therapy for Wet AMD in early 2025.
• Roche expanded its portfolio with the release of a new photodynamic therapy product aimed at early-stage Dry AMD in mid-2024.
• Bayer acquired a stake in a biotechnology startup focused on gene therapy for macular degeneration in Q3 2024.
• Pfizer unveiled a new corticosteroid-based treatment for macular degeneration, showing promising results in clinical trials.

List of Leading Companies:

• Novartis
• Regeneron Pharmaceuticals
• Roche
• Bayer
• Pfizer
• Biogen
• Apellis Pharmaceuticals
• Apotex
• Allergan (AbbVie)
• Santen Pharmaceutical
• Genentech (a Roche Company)
• IVERIC bio
• Alimera Sciences
• Kala Pharmaceuticals
• Belite Bio

Report Scope: